Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 19.2 Million CHF | 17.51% |
| 2022 | 16.34 Million CHF | 1294.45% |
| 2021 | 1.17 Million CHF | 105.04% |
| 2020 | -23.25 Million CHF | -35.22% |
| 2019 | -17.2 Million CHF | 25.72% |
| 2018 | -23.15 Million CHF | -63.82% |
| 2017 | -14.13 Million CHF | 67.79% |
| 2016 | -43.88 Million CHF | 28.62% |
| 2015 | -61.48 Million CHF | -46.99% |
| 2014 | -41.83 Million CHF | -25.67% |
| 2013 | -33.28 Million CHF | 34.54% |
| 2012 | -50.84 Million CHF | 11.18% |
| 2011 | -57.25 Million CHF | -153.16% |
| 2010 | 107.68 Million CHF | 188.85% |
| 2009 | -121.2 Million CHF | 20.53% |
| 2008 | -152.5 Million CHF | -11.75% |
| 2007 | -136.46 Million CHF | -55.2% |
| 2006 | -87.93 Million CHF | -72.96% |
| 2005 | -50.83 Million CHF | 32.86% |
| 2004 | -75.71 Million CHF | -35.49% |
| 2003 | -55.88 Million CHF | 11.05% |
| 2002 | -62.82 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 9.25 Million CHF | 0.0% |
| 2023 Q4 | -17.69 Million CHF | 0.0% |
| 2023 Q2 | 36.89 Million CHF | 0.0% |
| 2023 FY | 19.2 Million CHF | 17.51% |
| 2022 Q4 | 27.58 Million CHF | 0.0% |
| 2022 Q2 | -9.04 Million CHF | 0.0% |
| 2022 FY | 16.34 Million CHF | 1294.45% |
| 2021 Q2 | -15.35 Million CHF | 0.0% |
| 2021 Q4 | 16.52 Million CHF | 0.0% |
| 2021 FY | 1.17 Million CHF | 105.04% |
| 2020 Q2 | -2.14 Million CHF | 0.0% |
| 2020 FY | -23.25 Million CHF | -35.22% |
| 2020 Q4 | -21.11 Million CHF | 0.0% |
| 2019 Q4 | -4 Million CHF | 0.0% |
| 2019 Q2 | -13.19 Million CHF | 0.0% |
| 2019 FY | -17.2 Million CHF | 25.72% |
| 2018 FY | -23.15 Million CHF | -63.82% |
| 2018 Q2 | -19.36 Million CHF | 0.0% |
| 2018 Q4 | -3.79 Million CHF | 0.0% |
| 2017 Q2 | -17.67 Million CHF | 0.0% |
| 2017 Q4 | 3.53 Million CHF | 0.0% |
| 2017 FY | -14.13 Million CHF | 67.79% |
| 2016 Q2 | -24.83 Million CHF | 0.0% |
| 2016 FY | -43.88 Million CHF | 28.62% |
| 2016 Q4 | -19.05 Million CHF | 0.0% |
| 2015 Q2 | -29.99 Million CHF | 0.0% |
| 2015 Q4 | -31.48 Million CHF | 0.0% |
| 2015 FY | -61.48 Million CHF | -46.99% |
| 2014 Q4 | -22.31 Million CHF | 0.0% |
| 2014 FY | -41.83 Million CHF | -25.67% |
| 2014 Q2 | -19.52 Million CHF | 0.0% |
| 2013 Q4 | -15.92 Million CHF | 0.0% |
| 2013 Q2 | -17.36 Million CHF | 0.0% |
| 2013 FY | -33.28 Million CHF | 34.54% |
| 2012 Q2 | -13.08 Million CHF | 0.0% |
| 2012 Q1 | -13.08 Million CHF | 0.0% |
| 2012 Q4 | -8.24 Million CHF | 36.96% |
| 2012 FY | -50.84 Million CHF | 11.18% |
| 2012 Q3 | -13.08 Million CHF | 0.0% |
| 2011 FY | -57.25 Million CHF | -153.16% |
| 2011 Q3 | -14.27 Million CHF | 0.0% |
| 2011 Q4 | -13.08 Million CHF | 8.31% |
| 2011 Q2 | -14.27 Million CHF | 0.0% |
| 2011 Q1 | -14.27 Million CHF | 0.0% |
| 2010 Q4 | -14.27 Million CHF | -152.77% |
| 2010 FY | 107.68 Million CHF | 188.85% |
| 2010 Q2 | 27.04 Million CHF | 0.0% |
| 2010 Q1 | 27.04 Million CHF | 0.0% |
| 2010 Q3 | 27.04 Million CHF | 0.0% |
| 2009 FY | -121.2 Million CHF | 20.53% |
| 2009 Q1 | -30.05 Million CHF | 0.0% |
| 2009 Q2 | -30.05 Million CHF | 0.0% |
| 2009 Q3 | -30.05 Million CHF | 0.0% |
| 2009 Q4 | 27.04 Million CHF | 189.99% |
| 2008 FY | -152.5 Million CHF | -11.75% |
| 2008 Q4 | -30.05 Million CHF | 16.24% |
| 2008 Q1 | -35.88 Million CHF | 0.0% |
| 2008 Q2 | -35.88 Million CHF | 0.0% |
| 2008 Q3 | -35.88 Million CHF | 0.0% |
| 2007 Q2 | -31.7 Million CHF | 0.0% |
| 2007 Q4 | -35.88 Million CHF | -13.18% |
| 2007 Q3 | -31.7 Million CHF | 0.0% |
| 2007 Q1 | -31.7 Million CHF | 0.0% |
| 2007 FY | -136.46 Million CHF | -55.2% |
| 2006 Q2 | -21.28 Million CHF | 0.0% |
| 2006 Q3 | -21.28 Million CHF | 0.0% |
| 2006 Q4 | -31.7 Million CHF | -48.94% |
| 2006 FY | -87.93 Million CHF | -72.96% |
| 2006 Q1 | -21.28 Million CHF | 0.0% |
| 2005 Q4 | -21.28 Million CHF | -72.23% |
| 2005 Q3 | -12.35 Million CHF | 0.0% |
| 2005 Q1 | -12.35 Million CHF | 0.0% |
| 2005 Q2 | -12.35 Million CHF | 0.0% |
| 2005 FY | -50.83 Million CHF | 32.86% |
| 2004 FY | -75.71 Million CHF | -35.49% |
| 2004 Q1 | -18.86 Million CHF | 0.0% |
| 2004 Q2 | -18.86 Million CHF | 0.0% |
| 2004 Q3 | -18.86 Million CHF | 0.0% |
| 2004 Q4 | -12.35 Million CHF | 34.49% |
| 2003 Q1 | -13.91 Million CHF | 0.0% |
| 2003 Q3 | -13.91 Million CHF | 0.0% |
| 2003 Q4 | -18.86 Million CHF | -35.62% |
| 2003 Q2 | -13.91 Million CHF | 0.0% |
| 2003 FY | -55.88 Million CHF | 11.05% |
| 2002 Q3 | -14.74 Million CHF | 0.0% |
| 2002 FY | -62.82 Million CHF | 0.0% |
| 2002 Q2 | -14.74 Million CHF | 0.0% |
| 2002 Q1 | -14.74 Million CHF | 0.0% |
| 2002 Q4 | -13.91 Million CHF | 5.63% |
| 2001 Q4 | -14.74 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | 286.254% |
| BB Biotech AG | -29.92 Million CHF | 164.171% |
| Evolva Holding SA | -92.24 Million CHF | 120.819% |
| Idorsia Ltd | -543.05 Million CHF | 103.536% |
| Kuros Biosciences AG | -13.19 Million CHF | 245.581% |
| Molecular Partners AG | -61.1 Million CHF | 131.428% |
| Relief Therapeutics Holding AG | -110.82 Million CHF | 117.329% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 72.104% |